Digraph

2020-02 Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia
Broad-Spectrum Antibiotics Ineffective as Initial Pneumonia Treatment - Critical Care - Hospimedica.comhttps://www.hospimedica.com/critical-care/articles/294781065/broad-spectrum-antibiotics-ineffective-as-initial-pneumonia-treatment.html
2020-02 Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia
Broad-spectrum antibiotics and initial pneumonia treatment | @theUhttps://attheu.utah.edu/facultystaff/no-benefit-found-in-using-broad-spectrum-antibiotics-as-initial-pneumonia-treatment/
2020-02 Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia
Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia | Infectious Diseases | JAMA Internal Medicine | JAMA Networkhttps://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2760778
2020-02 Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia
Pneumonia Mortality Not Improved With Empiric Anti-MRSA Therapy - Infectious Disease Advisorhttps://www.infectiousdiseaseadvisor.com/home/topics/respiratory/adding-anti-mrsa-antibiotic-linked-to-increased-mortality-in-patients-with-pneumonia/
2020-02 Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia

Showing topic

2020-02 Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia
Empiric use of antibioticsStudies of MRSA